473 related articles for article (PubMed ID: 30801221)
1. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
[TBL] [Abstract][Full Text] [Related]
2. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
3. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
5. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
[No Abstract] [Full Text] [Related]
6. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
7. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
8. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
Marinas JE; Kim WB; Shahbaz A; Qiang JK; Greaves S; Yeung J
Australas J Dermatol; 2018 Feb; 59(1):e11-e14. PubMed ID: 27858976
[TBL] [Abstract][Full Text] [Related]
9. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.
van der Schoot LS; van den Reek JMPA; Groenewoud JMM; Otero ME; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Berends MAM; Arnold WP; Peters B; Andriessen MPM; Den Hengst CW; Kuijpers ALA; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1913-1920. PubMed ID: 31177583
[TBL] [Abstract][Full Text] [Related]
10. Evolving Landscape of Biologic Therapy for Pediatric Psoriasis.
Do H; Babbush Graber K; Chernoff KA; Melnick LE
Dermatol Clin; 2024 Jul; 42(3):377-386. PubMed ID: 38796269
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Medina-Gil C; Dehesa L; Vega A; Kerdel F
Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
[TBL] [Abstract][Full Text] [Related]
13. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
14. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
16. New targets in psoriatic arthritis.
Braun J
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
[TBL] [Abstract][Full Text] [Related]
17. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.
Bartos G; Cline A; Beroukhim K; Burrall BA; Feldman SR
Dermatol Online J; 2018 Nov; 24(11):. PubMed ID: 30695971
[TBL] [Abstract][Full Text] [Related]
18. Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis.
Blauvelt A; Armstrong AW; Krueger GG
J Drugs Dermatol; 2015 Aug; 14(8):805-12. PubMed ID: 26267724
[TBL] [Abstract][Full Text] [Related]
19. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald JM; Klufas DM; Strober BE
J Drugs Dermatol; 2015 Aug; 14(8):888-92. PubMed ID: 26267735
[TBL] [Abstract][Full Text] [Related]
20. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Menter A; Strober BE; Kaplan DH; Kivelevitch D; Prater EF; Stoff B; Armstrong AW; Connor C; Cordoro KM; Davis DMR; Elewski BE; Gelfand JM; Gordon KB; Gottlieb AB; Kavanaugh A; Kiselica M; Korman NJ; Kroshinsky D; Lebwohl M; Leonardi CL; Lichten J; Lim HW; Mehta NN; Paller AS; Parra SL; Pathy AL; Rupani RN; Siegel M; Wong EB; Wu JJ; Hariharan V; Elmets CA
J Am Acad Dermatol; 2019 Apr; 80(4):1029-1072. PubMed ID: 30772098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
